Wells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $262.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by Wells Fargo & Company from $260.00 to $262.00 in a research report report published on Friday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on ASND. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an overweight rating in a research report on Friday. Cantor Fitzgerald restated an overweight rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Friday. Wedbush raised their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a report on Thursday, February 8th. Citigroup upped their price target on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a research note on Thursday, February 8th. Finally, Morgan Stanley reissued an equal weight rating and issued a $116.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, April 22nd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $173.88.

Ascendis Pharma A/S Trading Down 2.8 %

Shares of ASND stock opened at $137.20 on Friday. The stock’s fifty day simple moving average is $146.67 and its 200-day simple moving average is $128.07. The company has a market capitalization of $7.99 billion, a price-to-earnings ratio of -14.28 and a beta of 0.54. Ascendis Pharma A/S has a 1-year low of $83.75 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $0.49. The firm had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ASND. Certuity LLC bought a new position in Ascendis Pharma A/S during the fourth quarter worth $270,000. Invesco Ltd. lifted its stake in shares of Ascendis Pharma A/S by 9.3% in the third quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock valued at $62,938,000 after buying an additional 57,413 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $1,810,000. Schonfeld Strategic Advisors LLC grew its position in Ascendis Pharma A/S by 24.7% during the third quarter. Schonfeld Strategic Advisors LLC now owns 38,900 shares of the biotechnology company’s stock worth $3,643,000 after buying an additional 7,700 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at about $732,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.